Is ABS-301 at ABCSI our drug? It’s not disclosed correct? Who owns that drug or what drug it is?

Watching the presentation now interesting.

“Stegmann also explained how Absci's reverse immunology technology​ elucidated a potentially novel mechanism of tumor immune evasion in conjunction with the development of ABS-301, which has broad first-in-class potential in immuno-oncology. Stegmann said that several other undisclosed assets are in the target evaluation stage. Find a recording of his full presentation here.”